Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting
LEXINGTON, Mass. --(BUSINESS WIRE)--Feb. 11, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
LEXINGTON, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia.
View HTML
Toggle Summary Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata
LEXINGTON, Mass. --(BUSINESS WIRE)--Jan. 22, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata.
View HTML
Toggle Summary Concert Pharmaceuticals Initiates Phase 1 Clinical Program of CTP-692 for the Treatment of Schizophrenia
LEXINGTON, Mass. --(BUSINESS WIRE)--Dec. 17, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-692, which is being developed as a novel adjunctive treatment for schizophrenia, a devastating, chronic illness with
View HTML
Toggle Summary Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata
CTP-543 Achieved its Primary Endpoint in the 8 mg Twice-Daily Cohort Company to Host Investor Conference Call Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 12, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of
View HTML
Toggle Summary Concert Pharmaceuticals to Participate at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 7, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2018 Healthcare Conference on November 14, 2018 , at 2:00 p.m.
View HTML
Toggle Summary Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine
Findings Presented at American College of Toxicology 2018 Annual Meeting LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 5, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented preclinical results that support the potential of CTP-692, the Company’s novel drug candidate for schizophrenia,
View HTML
Toggle Summary Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Company Update
Conference Call Scheduled Today at 8:30 a.m. ET LEXINGTON, Mass. --(BUSINESS WIRE)--Nov. 1, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2018. “This is an exciting time at Concert as we advance multiple pipeline candidates, with our
View HTML
Toggle Summary Concert Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 1, 2018
LEXINGTON, Mass. --(BUSINESS WIRE)--Oct. 25, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2018 financial results on Thursday, November 1, 2018 , before the U.S. financial markets open. The Company will host a conference call and webcast
View HTML
Toggle Summary Concert Pharmaceuticals Amends Protocol of Phase 2a Trial to Evaluate 12 mg Twice-Daily Dose Cohort of CTP-543 for the Treatment of Alopecia Areata
Company On Track to Report Topline Data from the 4 mg and 8 mg Twice-Daily Cohorts in Fourth Quarter of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 26, 2018-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial
View HTML